Your shopping cart is empty!
FDA Approves Tavalisse (fostamatinib) For The Treatment Of Chronic Immune Thrombocytopenia (ITP)
- Hits: 84
US FDA Gave Green Signal To Tavalisse for the treatment of chronic immune thrombocytopenia (ITP)
U.S. FDA (Food and Drug Administration) extends its approval for Tavalisse (fostamatinib) for the treatment of chronic immune thrombocytopenia (ITP)
Company: Rigel Pharmaceutical Inc.
Brand Name: Tavalisse
Generic Name: fostamatinib
Treatment For: Idiopathic (Immune) Thrombocytopenic Purpura
General information about Tavalisse
Tavalisse (fostamatinib) is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of patients with chronic immune thrombocytopenia (ITP).